Established cell lines typically need exogenous trypsin for multicycle growth of influenza A virus because viral haemagglutinin (HA) requires proteolytic cleavage to mediate membrane fusion. The authors examined several Madin-Darby canine kidney (MDCK) sublines and reported that MDCK-NBL2, MDCK-I, and MDCK-II supported multicycle, trypsin-independent replication across human, porcine and avian IAV strains. This pattern was consistent across the sublines named. The source did not provide full experimental parameters in the abstract; detailed methods, including multiplicities of infection and exact cell-culture conditions, are described in the full manuscript and should be consulted for reproduction of the results.
Investigators treated permissive MDCK sublines with the serine protease inhibitors camostat and nafamostat mesylate and observed dose-dependent reductions in viral replication. The reduction in replication tracked with increasing inhibitor concentration. The source notes a diminishing inhibitory effect when viral dose increased; the study team proposed that higher virion numbers likely compete with inhibitors for binding to the protease, reducing apparent inhibitor efficacy. The abstract did not list specific inhibitor concentrations or pharmacodynamic parameters; those experimental details are provided in the full text.
The authors probed endogenous expression of transmembrane serine proteases in the MDCK sublines and detected several, explicitly including canine TMPRSS2 and TMPRSS4. Expression patterns varied between sublines. The study team used localization assays to compare the two proteases and reported that canine TMPRSS4 predominantly localizes to the plasma membrane, whereas canine TMPRSS2 did not show the same membrane-enriched distribution. These localization differences, the authors suggested, could influence access to incoming virions and thereby affect HA activation efficiency.
Functional characterization of the two canine proteases indicated differential capacity to cleave and activate HA from various influenza virus strains. Investigators found that canine TMPRSS4 was more effective than TMPRSS2 at proteolytic activation of multiple IAV strains, but they also noted strain-dependent variability in activation efficiency. The result implies that both the host protease and viral HA sequence contribute to whether cleavage and subsequent entry can occur without exogenous trypsin. The abstract does not include exact quantitative readouts, cleavage kinetics, or strain-by-strain comparative data; readers should refer to the main figures and tables in the manuscript for numeric results.
The manuscript is posted as a preprint and has not been certified by peer review, a detail the authors explicitly report. The abstract does not provide comprehensive experimental parameters—such as inhibitor molarity, time courses, or sample sizes—so the reader must consult the full paper to assess reproducibility and robustness. The authors also indicate that inhibitor potency fell with higher viral inocula, a finding they interpret as competitive binding; however, formal mechanistic proof of that competition was not described in the abstract. Strain-dependent differences in protease activation were observed, but the determinants that drive those differences require further mapping. Finally, while the study identifies MDCK sublines that express functional HA-activating proteases, the clinical relevance of these in vitro findings—particularly for antiviral development and predictive testing—will depend on follow-up work, validation in other model systems, and peer review.
The data presented offer practical considerations for laboratories that culture influenza A viruses: some MDCK sublines may be used without exogenous trypsin, which could alter assay outputs and antiviral screening results. The authors recommend consulting the full manuscript for detailed methods and for the quantitative data that support the abstract observations. The paper ends by noting remaining questions about protease–HA interactions and the need for further validation; those items remain to be addressed in subsequent work.